Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Amphastar P (AMPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: AMPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit -6.1% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.38B USD | Price to earnings Ratio 9.47 | 1Y Target Price 39 |
Price to earnings Ratio 9.47 | 1Y Target Price 39 | ||
Volume (30-day avg) 654467 | Beta 0.77 | 52 Weeks Range 25.89 - 53.95 | Updated Date 04/1/2025 |
52 Weeks Range 25.89 - 53.95 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 21.79% | Operating Margin (TTM) 24.2% |
Management Effectiveness
Return on Assets (TTM) 8.31% | Return on Equity (TTM) 23.26% |
Valuation
Trailing PE 9.47 | Forward PE - | Enterprise Value 1809804506 | Price to Sales(TTM) 1.89 |
Enterprise Value 1809804506 | Price to Sales(TTM) 1.89 | ||
Enterprise Value to Revenue 2.47 | Enterprise Value to EBITDA 6.53 | Shares Outstanding 47650100 | Shares Floating 36703935 |
Shares Outstanding 47650100 | Shares Floating 36703935 | ||
Percent Insiders 22.92 | Percent Institutions 76.09 |
Analyst Ratings
Rating 4 | Target Price 56.4 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Amphastar P
Company Overview
History and Background
Amphastar Pharmaceuticals, Inc. was founded in 1996. They are a specialty pharmaceutical company focused on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable products. A significant milestone was its IPO and subsequent growth in the injectable market.
Core Business Areas
- Finished Pharmaceutical Products: Focuses on the development, manufacture and sale of generic and proprietary injectable and intranasal dosage form products.
- API: Engaged in development, manufacture and sale of active pharmaceutical ingredient (API) products used in pharmaceutical products.
Leadership and Structure
The leadership team is headed by the CEO, and the organizational structure consists of various departments including R&D, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- Enoxaparin: A generic version of Lovenox, an anticoagulant. Market share fluctuates but Amphastar is a major player. Competitors include Sandoz and Teva Pharmaceutical Industries. Market share not available.
- Epinephrine: Anaphylaxis treatment. Amphastar holds a significant market share, particularly in the generic segment. Competitors include Mylan (Viatris) and Teva. Market share not available.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, innovation, and stringent regulatory requirements. The injectables market is growing due to factors such as an aging population and increased prevalence of chronic diseases.
Positioning
Amphastar P is positioned as a specialty pharmaceutical company focusing on difficult-to-manufacture injectables. Its competitive advantage lies in its manufacturing capabilities and expertise in developing generic versions of complex drugs.
Total Addressable Market (TAM)
The TAM for injectables is estimated to be in the hundreds of billions of dollars. Amphastar is positioned to capture a portion of this TAM through its focus on niche products and generic offerings.
Upturn SWOT Analysis
Strengths
- Strong manufacturing capabilities
- Expertise in developing complex injectables
- Established distribution network
- Vertically integrated API production
Weaknesses
- Reliance on a limited number of products
- Exposure to regulatory risks
- Dependence on third-party suppliers
- Potential for product recalls
Opportunities
- Expansion into new therapeutic areas
- Acquisition of complementary businesses
- Increased demand for generic injectables
- Growing adoption of biosimilars
Threats
- Increased competition from other generic manufacturers
- Price erosion
- Changes in regulatory requirements
- Patent litigation
Competitors and Market Share
Key Competitors
- Teva Pharmaceutical Industries (TEVA)
- Mylan (Viatris) (VTRS)
- Sandoz (part of Novartis, NVS)
- Hikma Pharmaceuticals (HKMPY)
Competitive Landscape
Amphastar P competes primarily on price and product availability. Its advantages include its manufacturing capabilities and vertically integrated API production. Disadvantages include its reliance on a limited number of products.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth data depends on readily available data from financial news sources. Access to that is required to determine details
Future Projections: Future projections depend on analyst estimates. Access to that is required to determine details
Recent Initiatives: Recent initiatives include product development and regulatory approvals.
Summary
Amphastar P is a specialty pharmaceutical company with a focus on injectables and API, characterized by strong manufacturing skills and strategic market positioning in niche segments. The company benefits from the growing demand for generic injectable products and vertical integration of API, but also faces competitive challenges and regulatory risks. Future success hinges on developing new products and acquisitions. The stock represents a moderate risk/reward within the pharmaceutical sector.
Similar Companies
- TEVA
- VTRS
- NVS
- HKMPY
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (FactSet, etc.)
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data is dynamic and subject to change. Financial figures are not real-time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amphastar P
Exchange NASDAQ | Headquaters Rancho Cucamonga, CA, United States | ||
IPO Launch date 2014-06-25 | Co-Founder, President, CEO, Chief Scientific Officer & Director Dr. Yongfeng Zhang Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2028 | Website https://www.amphastar.com |
Full time employees 2028 | Website https://www.amphastar.com | ||
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.